相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Personalized chordoma organoids for drug discovery studies
Ahmad Al Shihabi et al.
SCIENCE ADVANCES (2022)
Chordoma A Review and Differential Diagnosis
Veronica Ulici et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2022)
Advances in the development of chordoma models for drug discovery and precision medicine
Robert L. Walker et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)
Emerging target discovery and drug repurposing opportunities in chordoma
Daniel M. Freed et al.
FRONTIERS IN ONCOLOGY (2022)
PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells
Kaibing Tian et al.
FRONTIERS IN SURGERY (2022)
Chordoma-Current Understanding and Modern Treatment Paradigms
Sean M. Barber et al.
JOURNAL OF CLINICAL MEDICINE (2021)
mTORC1 promotes malignant large cell/anaplastic histology and is a targetable vulnerability in SHH-TP53 mutant medulloblastoma
Valentina Conti et al.
JCI INSIGHT (2021)
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
Marta Sbaraglia et al.
PATHOLOGICA (2021)
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy
N. L. Michmerhuizen et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou et al.
CELL AND BIOSCIENCE (2020)
Chordoma: update on disease, epidemiology, biology and medical therapies
Anna Maria Frezza et al.
CURRENT OPINION IN ONCOLOGY (2019)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt
Paola Zordan et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression
Ellie Rad et al.
CANCERS (2018)
The driver landscape of sporadic chordoma
Patrick S. Tarpey et al.
NATURE COMMUNICATIONS (2017)
Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis
Kangwu Chen et al.
MEDICAL ONCOLOGY (2014)
Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1
Edwin Choy et al.
PLOS ONE (2014)
Chordoma: current concepts, management, and future directions
Brian P. Walcott et al.
LANCET ONCOLOGY (2012)
Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population
Mary L. McMaster et al.
JOURNAL OF MEDICAL GENETICS (2011)
Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target Laboratory investigation
Wesley Hsu et al.
JOURNAL OF NEUROSURGERY (2011)
Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
N. Presneau et al.
BRITISH JOURNAL OF CANCER (2009)
Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas
Sangyeul Han et al.
CLINICAL CANCER RESEARCH (2009)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas
S. Vujovic et al.
JOURNAL OF PATHOLOGY (2006)
Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2
L Lee-Jones et al.
GENES CHROMOSOMES & CANCER (2004)
Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CHI
S Scheil et al.
GENES CHROMOSOMES & CANCER (2001)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
MS Neshat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)